Last reviewed · How we verify

NCT05947019

Efficacy and Safety of Low-Level Monochromatic Red-Light for High Myopia Control in Adults

Status unknown NA Last updated 14 July 2023
What this trial tests

NA trial testing Myopic amblyopia comprehensive treatment instrument in High Myopia in 60 participants. Status unknown.

Timeline
1 August 2023
Primary endpoint
1 October 2024
1 October 2025

Quick facts

Lead sponsorShanghai Eye Disease Prevention and Treatment Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 August 2023
Primary completion1 October 2024
Estimated completion1 October 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Eye Disease Prevention and Treatment Center — full company profile →

Who can join

Adults 18 to 40, any sex, with High Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical study is to confirm the effectiveness and safety of low-level monochromatic red-light for high myopia control in adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for High Myopia

Currently open trials in the same condition.

Other Shanghai Eye Disease Prevention and Treatment Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05947019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing